Actively Recruiting
Cohort for Monitoring Patients With Venous Thromboembolic Disease
Led by University Hospital, Rouen · Updated on 2025-06-11
2000
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Venous thromboembolic disease is a common condition affecting many people, with the risk of recurrence largely depending on whether the initial blood clot was provoked by a known factor. Patients who have unprovoked thromboembolic events face a higher chance of recurrence, leading clinicians to often continue anticoagulant treatments long-term. However, these treatments carry risks such as bleeding and are a leading cause of hospitalization due to side effects, so balancing treatment benefits and risks is crucial. This research evaluates tools used to guide treatment decisions for patients with venous thromboembolic disease, including bleeding risk scores like HAS BLED and VTE BLED, and recurrence risk scores such as HERDOO2. Since 2015, multidisciplinary thrombosis meetings have been held to support clinicians in managing complex cases, along with dedicated post-emergency consultations for less severe patients. Participants in this observational study who have had at least one venous thromboembolic event will be followed for up to 12 years. Researchers will monitor rates of recurrence and bleeding complications, as well as long-term complications, through initial enrollment and regular follow-up visits. The study aims to improve patient management by assessing the usefulness of these risk scores and multidisciplinary approaches in real-world care.
CONDITIONS
Brief Title
Cohort for Monitoring Patients With Venous Thromboembolic Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any patient over 18 years of age who has experienced at least one venous thromboembolic episode, including deep vein thrombosis confirmed by Doppler ultrasound or CT venography, or pulmonary embolism confirmed by CT angiography, ventilation/perfusion scan, or a confirmed DVT episode with respiratory signs consistent with PE
- Hospitalization in the Internal Medicine Department
- Consultation by an Internal Medicine physician
- Case presented at the thrombosis multidisciplinary meeting
You will not qualify if you...
- Thrombosis types not meeting the inclusion criteria, such as cerebral venous thrombosis or mesenteric thrombosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 years
Participants who have experienced a venous thromboembolic episode are observed over time to evaluate recurrence and bleeding complications, as well as long-term complication rates.
Visits at enrollment, 6 months, 1 year, and annually up to 12 years
Trial Site Locations
Total: 1 location
1
University Hospital of Rouen
Rouen, France, 76031
Actively Recruiting
Research Team
D
David DM MALLET, Director
V
Vincent VF FERRANTI, ARC
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here